Leiden, The Netherlands, June 25, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high […]
CureDuchenne is pleased to announce a partnership with the Duchenne Therapy Network to provide training to physical therapists as well as Duchenne families and caregivers about specialized care for Duchenne […]
CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, issued the following statement today regarding the announcement by Prosensa […]
PTC Therapeutics announced this morning that they have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, regarding the company’s […]
Dear Patient Group Representative, We trust this letter finds you well. As announced in a press release and during our quarterly update for the financial community […]
Sarepta Therapeutics, Inc. will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Tuesday, May 13, 2014, beginning at 11:00 am EDT (8:00 am […]
Re-dosing plans are underway and 96-week data from an open-label extension study of drisapersen for the treatment of DMD presented at the American Academy of Neurology (AAN) Leiden, The Netherlands, […]
CureDuchenne is pleased to share the following information from Prosensa. Dear Patient Group Representative, As we continue to receive all of the materials, data and know-how from GSK regarding […]
April 28, 2014, 8:32 a.m. EDT CAMBRIDGE, Mass., Apr 28, 2014 (BUSINESS WIRE) — Sarepta Therapeutics, Inc. /quotes/zigman/10874508/delayed/quotes/nls/srpt SRPT +1.17% , a developer of innovative RNA-based therapeutics, will host a webcast and conference […]
